Skip to main content
Christoph Sayed, MD, Dermatology, Chapel Hill, NC

ChristophJohnSayedMD

Dermatology • Chapel Hill, NC

Professor of Dermatology

Join to view full profile

Dr. Sayed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sayed's full profile

Already have an account?

  • Office

    101 Manning Dr
    Department of Internal Medicine
    Chapel Hill, NC 27514
    Phone+1 919-966-1072
    Fax+1 919-843-2356

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Dermatology, 2010 - 2013
  • University of North Carolina Hospitals
    University of North Carolina HospitalsInternship, Internal Medicine, 2009 - 2010
  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 2009

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2025
  • American Board of Dermatology Dermatology

Clinical Trials

Publications & Presentations

PubMed

Books/Book Chapters

  • Reichel’s Care for the Elderly, 7th ed. 
    Chapter: Geriatric Dermatology 
    Sayed C, Varman K.Editors: Busby-Whitehead J, Arenson C.. Cambridge University Press, New York2016
  • Frontiers in Gastrointestinal Research. 
    Chapter: Psoriasis-like Lesions and Skin Reactions (Chapter). In Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease. 
    Page 119 - 125Herfarth H, Long M, Sayed C.Editors: Rogler G, Herfarth H, Toshifumi H, Nielsen OH..KargerEdition 34,2015
  • Pathology: A Modern Case Study. 
    Chapter: Pathology of the Skin 
    Miedema J, Sayed C, Zedek D.Editors: Reisner, H..McGraw-Hill. , New YorkEdition 1,2014

Lectures

  • Advanced Management Strategies for Hidradenitis Suppurativa 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
  • Development of the North American Clinical Guidelines for Hidradenitis Suppurativa 
    American Academy of Dermatology Annual Meeting, Orlando, FL. - 2/2018
  • Office-Based Procedures for Hidradenitis Suppurativa 
    American Academy of Dermatology Annual Meeting, Orlando, FL - 2/2018

Press Mentions

  • Diagnosing Mild Hidradenitis Suppurativa: Early Stage Can Mimic Other Diseases
    Diagnosing Mild Hidradenitis Suppurativa: Early Stage Can Mimic Other DiseasesMay 21st, 2024

Research History

  • Co-investigatorA Phase 4, Double-Blind, Randomised,Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa.2018 - Present
  • Principal InvestigatorGenome-wide association study of patients with hidradenitis suppurativa.2018 - Present
  • Principal Investigator• UCB Biopharma SPRL, HS0001, A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Pharmacokinetics Of Bimekizumab In Subjects With Moderate To Severe Hidradenitis Suppurativa (HS).2018 - Present
  • Principal InvestigatorA randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa (SHINE). 2018.2018 - Present
  • Co-investigatorA Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.2017 - Present
  • Co-investigatorAn Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult Patients with Hidradenitis Suppurativa.2014 - Present
  • Co-investigatorA 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficac2016 - 2018
  • Principal InvestigatorFull transcriptome analysis in lesional and non-lesional skin of hidradenitis suppurativa with intention to identify disease signatures and understand molecular mechanism of disease.2016 - 2018
  • Co-investigatorSafety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis2017 - 2017
  • Principal InvestigatorA randomized, controlled, double blind study to evaluate the efficacy of intralesional triamcinolone in the treatment of hidradenitis suppurativa.2016 - 2017
  • Co-investigatorA Phase IIa, Randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability and preliminary efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa (HS).2014 - 2015

Professional Memberships

Dr. Christoph Sayed, Dr. Christoph Sayed, MD, Dr. C Sayed, Dr. Christoph John Sayed